Reporter brief
RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An Exploratory PK/PD Study of mTOR Inhibition in Older Human Subjects
What happened
Trial registry update: RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Whether mTOR inhibition at these doses improves any health outcomes, lifespan, or age-related disease prevention in older humans
- Whether animal model findings showing slowed aging from mTOR inhibitors translate to human benefit
- Whether observed pharmacokinetic/pharmacodynamic targets are clinically meaningful or associated with any therapeutic effect
Study design and sample
Rct; Human.
Healthy older adults, including both male and female subjects
- Design
- Rct
- Sample
- —
- Journal
- The University of Texas Health Science Center at San Antonio
- Published
- Jun 1, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.